Table 1 Baseline patient characteristics.
Characteristic | Sintilimab (N = 95) | Chemo (N = 95) |
|---|---|---|
Age, years | ||
Median (IQR) | 60 (54–64) | 60 (54–64) |
<65 | 74 (77.9%) | 75 (78.9%) |
≥65 | 21 (22.1%) | 20 (21.1%) |
Sex | ||
Male | 88 (92.6%) | 84 (88.4%) |
Female | 7 (7.4%) | 11 (11.6%) |
ECOG PS | ||
0 | 23 (24.2%) | 23 (24.2%) |
1 | 72 (75.8%) | 72 (75.8%) |
Pathological diagnosis | ||
Squamous cell carcinoma | 95 (100%) | 95 (100%) |
Disease stagea | ||
IIIA | 2 (2.1%) | 3 (3.2%) |
IIIB | 1 (1.1%) | 0 |
IIIC | 4 (4.2%) | 3 (3.2%) |
IV | 86 (90.5%) | 89 (93.7%) |
Site of metastases | ||
Lymph node | 67 (70.5%) | 64 (67.4%) |
Liver | 27 (28.4%) | 33 (34.7%) |
Lung | 37 (38.9%) | 46 (48.4%) |
Bone | 6 (6.3%) | 6 (6.3%) |
Other | 31 (32.6%) | 32 (33.7%) |
PD-L1 expression | ||
Combined Positive Score <1 | 11 (11.6%) | 17 (17.9%) |
Combined Positive Score ≥1 | 63 (66.3%) | 50 (52.6%) |
Combined Positive Score <10 | 34 (35.8%) | 47 (49.5%) |
Combined Positive Score ≥10 | 40 (42.1%) | 20 (21.1%) |
Tumor Proportion Score <1% | 44 (46.3%) | 43 (45.3%) |
Tumor Proportion Score ≥1% | 30 (31.6%) | 24 (25.3%) |
Tumor Proportion Score <10% | 60 (63.2%) | 53 (55.8%) |
Tumor Proportion Score ≥10% | 14 (14.7%) | 14 (14.7%) |
Not evaluable | 21 (32.6%) | 28 (33.7%) |
Previous treatment | ||
First-line chemotherapy | 84 (88.4%) | 85 (89.5%) |
Prior to adjuvant chemotherpy (Disease progression within 6 months) | 11 (11.6%) | 10 (10.5%) |
Radiotherapy | 50 (52.6%) | 58 (61.1%) |
Surgery | 58 (61.1%) | 47 (49.5%) |
